Conceived and designed the experiments: DML DAL HMK WHB. Performed the experiments: MDN JB GS. Analyzed the data: MRN BP JLJ WHB DAL DML. Contributed reagents/materials/analysis tools: MDN JB GS HMK MN DJ PG AO SG LB. Wrote the paper: MRN BP DML. Acquisition of data: MDN JB GS HMK MN DJ PG AO SG LB. Article drafting and revisions: MRN BP HMK GS SG LB JLJ WHB DAL DML. Final manuscript approval: MRN BP MDN JB GS HMK MN DJ PG AO SG LB JLJ WHB DAL DML.
Biomarkers associated with response to therapy in tuberculosis could have broad clinical utility. We postulated that the frequency of
Objectives: We sought to determine the relationship of Mtb specific CD4+ T cells and CD8+ T cells with duration of antituberculosis treatment.
We performed a prospective cohort study, enrolling between June 2008 and August 2010, of HIV-uninfected Ugandan adults (n = 50) with acid-fast bacillus smear-positive, culture confirmed pulmonary TB at the onset of antituberculosis treatment and the Mtb specific CD4+ and CD8+ T cell responses to ESAT-6 and CFP-10 were measured by IFN-γ ELISPOT at enrollment, week 8 and 24.
There was a significant difference in the Mtb specific CD8+ T response, but not the CD4+ T cell response, over 24 weeks of antituberculosis treatment (
Our data provide evidence that the Mtb specific CD8+ T cell response declines with antituberculosis treatment and could be a surrogate marker of response to therapy. Additional research is needed to determine if the Mtb specific CD8+ T cell response can detect early treatment failure, relapse, or to predict disease progression.
Modern tools such as the GeneXpert® (Cepheid; Sunnyvale, California, USA) and line probe assays allow for the rapid identification of
Host factors such as cytokines, chemokines, immune cells, antibodies to Mtb, and differential gene expression profiles have all been investigated as potential biomarkers
We postulate that the poor correlation of IGRAs with treatment reflects the biological inability of the CD4+ T cell to discern differences in intracellular bacterial burden. IGRAs measure IFN-γ released by peripheral blood mononuclear cells (PBMC), which are dominated by CD4+ T cells
To study this question, we enrolled 50 HIV-negative subjects with AFB smear-positive pulmonary TB and measured the Mtb specific CD4+ and CD8+ T cell responses at three time points during antituberculosis treatment. Our data provide evidence that the number of Mtb specific CD8+ T cells, potentially by detecting intracellular mycobacterial antigen, and hence intracellular infection, declines with antituberculosis treatment and may be a surrogate marker of response to therapy. As a secondary analysis, to explore the differences in the Mtb specific CD4+ and CD8+ responses on antituberculous treatment, we sought to determine if baseline nutritional differences affected or altered the association between the Mtb specific CD8+ T cell response and treatment duration.
Some of these results have been previously reported in an oral/poster presentation
The study protocol was approved by the institutional review boards at the Joint Clinical Research Centre, Kampala, Uganda, University Hospitals Case Medical Center, Cleveland, Ohio, USA and U.S. Centers for Disease Control (CDC) and the Ugandan National Council for Science and Technology. Written informed consent was obtained from all study participants.
A prospective cohort study to evaluate microbial and immunologic surrogate markers in response to TB treatment was undertaken jointly by the CDC TB Trials Consortium (TBTC) and the NIAID's Tuberculosis Research Unit (TBRU) (TBTC Study NAA2m/DMID 08-0023) at the Uganda-Case Western Reserve University Collaboration sites in Kampala, Uganda. The study describing the microbial surrogate markers will be reported separately. Our study objectives were to evaluate the Mtb specific CD4+ and CD8+ T cell response during antituberculosis treatment.
Patients aged 18 to 60 years with suspected pulmonary TB presenting to the National TB Treatment Center at Mulago Hospital in Kampala, Uganda between June 2008 and August 2010 were evaluated. HIV-negative, sputum AFB smear-positive patients with cavitary disease, residing within a radius of 20 kilometers from the treatment center, no history of previous TB treatment, and a Karnofsky Performance Scale Score >50% (requires occasional assistance, but is able to care for most personal needs)
Culture medium consisted of RPMI 1640 supplemented with 10% human sera, 5×10−5 M 2 ME (Sigma-Aldrich,
To measure Mtb specific CD4+ and CD8+ T cell responses, overnight IFN-γ ELISPOT assays were performed as described previously
The ex - vivo frequency of Mtb specific T cells was calculated per time point, per person, as the average number of spot forming units (SFU) for wells containing antigen and compared with the average SFU in the control wells. To account for well-to-well variance among technical replicates, a standard deviation of the media control was calculated. A positive ELISPOT assay was defined as one in which the Mtb specific T cell response was at least two standard deviations above the background control. If these criteria were met, the mean of the background was subtracted out to enumerate the Mtb specific T cell response per 250,000 T cells. A positive PHA response was defined as ≥100 SFU per well.
To assess the overall change in the Mtb specific CD4+ and CD8+ T cell response over 24 weeks across 3 time points during antituberculosis treatment, a negative binomial mixed model for over-dispersed spot forming counts was used, with significance at 0.05. A negative binomial model was chosen and is appropriate for (1) ELISPOT count data (as opposed to continuous data), and (2) correlations within subjects when using repeated measures study design. Goodness of fit tests were performed to check model specifications and potential overdispersion or underdispersion in the Poisson regression. The generalized estimating equation (GEE) approach was adopted to estimate standard errors for the correlated data and the quasi-likelihood under the independent model criteria (QIC) for GEE was used to define optimal covariance structure.
Fifty-one, HIV-negative subjects with pulmonary TB were invited to participate in the study and baseline characteristics were collected from 50 subjects. The mean age of the clinical cohort was 26.6±6.0 years (
| Characteristics | |||
| Clinical | |||
| Females, n (%) | 12 (24) | ||
| Mean age (years ± standard deviation) | 26.6±6.0 | ||
| Body mass index at baseline (kg/m2 ± standard deviation) | 18.8±3.1 | ||
| Fever n (%) | 18 (36) | ||
| Night sweats n (%) | 24 (48) | ||
| Anorexia n (%) | 19 (38) | ||
| Extra-pulmonary TB n (%) | 8 (16) | ||
| Radiographic n (%) | |||
| Cavitation | |||
| Absent | 1 (2) | ||
| Single or multiple, diameter <4 cm in aggregate | 18 (36) | ||
| Single or multiple, diameter ≥4 cm in aggregate | 31 (62) | ||
| Extent | |||
| Limited, lesions <1/4 of thoracic cavity | 0 (0) | ||
| Moderate, lesions <½ of thoracic cavity | 19 (38) | ||
| Extensive, lesions involving >½ of thoracic cavity | 31 (62) | ||
| Pleural disease | 5 (10) | ||
| Total n (%) | 50 (100) | ||
| Diagnostic Test | Time Point | ||
| AFB smear grade n (%) | Baseline – Week 0 | Week 8 | Week 24 |
| 4+ | 29 (58) | 0 (0) | 0 (0) |
| 3+ | 14 (28) | 6 (12.2) | 0 (0) |
| 2+ | 5 (10) | 7 (14.3) | 0 (0) |
| 1+ | 2 (4) | 8 (16.3) | 3 (7) |
| Negative | 0 (0) | 28 (57.2) | 40 (93) |
| Missing data n | 0 | 1 | 7 |
| Mycobacterial growth on 7H10 solid media n (%) | |||
| >200 col. | 50 (100) | 0 (0) | 0 (0) |
| 20–100 col. | 0 (0) | 3 (6.1) | 0 (0) |
| <20 col. | 0 (0) | 10 (20.4) | 0 (0) |
| No growth | 0 (0) | 36 (73.5) | 40 (100) |
| Contamination | 0 | 0 | 5 |
| Missing data n | 0 | 1 | 5 |
| Total n (%) | 50 (100) | 49 (100) | 40 (100) |
Definition of abbreviations: col. = colonies
Total n (%) calculated less missing data and contamination
Blood was drawn at baseline, week 8 and week 24 of treatment for 49, 48, and 42 subjects respectively and interpretable ELISPOT results were available from all subjects. Ten subjects did not have blood drawn for at least one of the three time points for ELISPOT analysis, and 3 of the 10 subjects were missing blood from the week 8 and week 24 time points. The median mitogen or PHA responses (SFU) for the CD4 and CD8 ELISPOT were 204 (interquartile range of 144–373) and 193 (interquartile range 91 – 336) respectively at baseline. Using the same approach to assess the Mtb specific T cell responses during treatment as described in the methods, the response to PHA increased significantly with duration of treatment for both the CD4+ and CD8+ T cells. For the CD4+ T cells, the average response (SFU) to PHA at baseline, week 8 and week 24 was 248, 298, and 323 respectively with a significant difference during treatment (
We hypothesized that the frequency of Mtb specific CD8+ T cells could be used as a surrogate marker of response to therapy and would decrease during effective antituberculosis treatment. To test this hypothesis, we analyzed the Mtb specific CD4+ and CD8+ T cell response by IFN-γ ELISPOT in response to ESAT-6 and CFP-10 during antituberculosis treatment. Using a negative binomial mixed model, we first evaluated the overall change in the Mtb specific CD4+ and CD8+ T cell response over 24 weeks of antituberculosis treatment, independent of other variables. Taking into account all available time points (n = 3), there was a significant difference in the Mtb specific CD8+ T cell response during the 24 weeks of treatment (
The magnitude of the Mtb specific CD4+ T cell response (A) and Mtb specific CD8+ T cell response (B) is shown by IFN-γ ELISPOT in response to ESAT-6 and CFP-10 and reported in spot forming units per 250,000 T cells. Evaluable samples (n) analyzed per time point were 49, 48 and 42 for baseline, week 8 and week 24 respectively. A negative binomial mixed model was used to assess the overall change during 24 weeks. Raw data, surrounded by the box demonstrates the distribution of 25–75% of the data, with the whiskers representing the non-outlier data, and the horizontal line depicting the median. Raw data is shown with a triangle, outliers with a circle, and extremes with a star.
The waterfall plots show the absolute change in magnitude (SFU) between the baseline time point to week 8 for the Mtb specific CD4+ (A) and CD8+ (C) T cell response. The absolute change in magnitude for the baseline time point to week 24 is shown for the Mtb specific CD4+ (B) and CD8+ (D) T cell response. Black bars represent SFU decreasing from baseline to the respective time point, whereas white bars represent increasing SFU from baseline to the respective time point.
To explain this difference between the Mtb specific CD4+ and CD8+ T cell responses over the 24 weeks of treatment, we postulated that nutritional status could be differentially affecting Mtb specific CD4+ and CD8+ T cell responses. As a secondary analysis, we sought to determine whether an association between the Mtb specific CD4+ or CD8+ T response, if associated with time on treatment, might be correlated with malnutrition. In this regard, protein calorie malnutrition has been associated with reduced lymphocyte replication as well as a lower IFN-γ response in animal models
The magnitude of the Mtb specific T cell response by IFN-γ ELISPOT to ESAT-6 and CFP-10, and reported in spot forming units/250,000 T cells, is shown at baseline for the Mtb specific CD4+ response (A) and the Mtb specific CD8+ response (B) for BMI≤17 (n = 14) and >17 (n = 34). A negative binomial model was used to assess differences in the Mtb specific T cell responses and BMI≤17 and >17. Raw data, shown as a triangle, surrounded by the box demonstrates the distribution of 25–75% of the data, with the whiskers representing the non-outlier data, and the horizontal line depicting the median.
The subgroup of subjects, who started therapy with a BMI≤17 with baseline and week 24 analyzable ELISPOT data (n = 11) are shown. The magnitude of the Mtb specific T cell response is shown by IFN-γ ELISPOT to ESAT-6 and CFP-10 and reported in spot forming units per 250,000 T cells. Connected lines at baseline and week 24 reflect a individual subject's profile for the Mtb specific CD4+ T cell response (A) and the Mtb specific CD8+ T cell response (B).
| CD4+ T Cell Response ( | CD8+ T Cell Response ( | |||
| Predictor Variable | Univariate | Multivariate | Univariate | Multivariate |
| Treatment duration (weeks) | 0.0582 | 0.0699 | <0.0001 | <0.0001 |
| BMI | 0.0067 | 0.0136 | 0.9286 | 0.4995 |
| Gender (ref: female) | 0.4271 | n/a | 0.8982 | n/a |
| Age | 0.1204 | n/a | 0.3667 | n/a |
| AFB smear grade | 0.2975 | n/a | 0.2378 | n/a |
| Extent | 0.9007 | n/a | 0.3539 | n/a |
| Cavitation | 0.8037 | n/a | 0.7226 | n/a |
BMI is included in the multivariate model with treatment duration.
The association between variables and the Mtb specific T cell response was analyzed at the baseline time point.
Statistical method: a negative binomial mixed model.
AFB smear grade 0 (smear negative) to 4+.
Extent: limited or moderate versus extensive by chest radiograph.
Cavitation: ≤ 4 cm versus >4 cm.
n/a. not applicable.
To explore the association of malnutrition with the Mtb specific T cell response and treatment duration, we developed a multivariate model. Using a negative binomial mixed model, we evaluated the overall change in the Mtb specific CD4+ and CD8+ T cell response over 24 weeks of antituberculosis treatment, using BMI as a biomarker for nutritional status. Taking into account all available time points (n = 3), and BMI, the Mtb specific CD4+ T cell response was not significantly associated with treatment duration in the multivariate analysis (
We postulated that the Mtb specific CD8+ T cell response would be associated with other surrogates of bacterial burden such as AFB smear grade, delayed clearance of Mtb from sputum, or persistent culture positivity. However, baseline AFB smear grade was not associated with the magnitude of Mtb specific CD4+ or CD8+ T cell responses. Given the relative imprecision of the AFB smear grade, we sought to determine if quantitative mycobacterial cultures (CFU) were associated with Mtb specific CD4+ or CD8+ T cell responses. Of the 50 subjects with baseline and follow up microbiologic data, 35 (70%) had quantitative mycobacterial cultures performed at baseline and 14 (28%) again at week 4. Given the paucity of data at 4 weeks and lack of matching blood draw at that time, only the baseline data were analyzed. Using a negative binomial model, we found that baseline quantitative mycobacterial cultures of sputum were not correlated with the magnitude of the Mtb specific CD4+ or CD8+ T cell response (data not shown). We also postulated that subjects with delayed mycobacterial clearance or treatment failure would have persistently elevated Mtb specific CD8+ T cell responses. However, as shown in
Quantitative cultures from subjects with smear positive pulmonary TB as shown by the log of colony forming units (CFU) enumerated on 7H10 media at week 0 (n = 35) and week 4 (n = 14). Raw data, shown as a triangle, surrounded by the box demonstrates the distribution of 25–75% of the data, with the whiskers representing the non-outlier data, and the horizontal line depicting the median. The dotted line connects the median points. Wilcoxon signed rank test was performed comparing subjects with week 0 and week 4 (n = 12).
We have demonstrated that the estimated Mtb specific CD8+ T cell response decreased by 58.4% at 24 weeks, with the majority of the decrease noted (38.7%) at 8 weeks in subjects receiving successful antituberculosis treatment. Surrogates of bacterial burden and response to therapy for Mtb infection have enormous potential in clinical practice to improve the management of those exposed to the Mtb, and those with TB disease. Among those who have been infected, but do not have TB disease, such markers might serve to reflect bacterial eradication, containment, growth or new exogenous infection. In this regard, such a marker might facilitate the identification of those who will progress to TB or, among subjects with TB disease, provide early identification of individuals at risk for treatment failure or relapse after treatment. Because CD8+ T cells recognize antigen derived from the intracellular environment, it is biologically plausible that they may discern a gradient of infection and distinguish infection from exposure. In this regard, the Mtb specific CD8 response in animal models correlates with bacterial load as demonstrated by the correlation with in vivo growth of Mtb
To our knowledge, this is the first study in humans to prospectively evaluate changes in the Mtb specific CD8+ T cell response from the peripheral blood during TB treatment. We demonstrate a significant difference in the Mtb specific CD8+ T cell response during antituberculosis treatment, with a decline of 58% at 24 weeks. Interestingly, the majority of the overall decline, nearly 39%, occurred within 8 weeks and was relatively unaffected by malnutrition. In contrast, we found that the Mtb specific CD4+ T cell response exhibited substantial variability. In a parallel multivariate analysis, the Mtb specific CD4+ T cell response showed a marginal difference over 24 weeks (
Our finding that there is an early decline in the Mtb specific CD8+ response during the initial phase of successful TB treatment suggests that the Mtb specific CD8+ T cell response, potentially by detecting intracellular bacterial burden, may be a more accurate, and direct surrogate of response to therapy than the CD4+ response. Alternatively, it is possible that the Mtb specific CD4+ T cell response is more confounded by other host factors such as malnutrition, although our results do not support malnutrition as the sole explanation for the poor association between the Mtb specific CD4+ T cell response and duration of treatment over 24 weeks of antituberculosis therapy. The effects of malnutrition on immune dysregulation are well known
In the mouse model, removal of antigen leads T cells to transition from cytokine producing effector T cells to those without short-term effector capacity
Our study has several unsettled points that need further study. Neither AFB smear grade, nor quantitative cultures were associated with the frequency of Mtb specific CD8+ T cell responses. From these data, as well as the observation of high frequency CD8+ T cell responses in those with LTBI
A further limitation was the use of ESAT-6 and CFP-10 in conjunction with IFN-γ as the immunological endpoint. In this regard, identification of novel Mtb antigens that are either disease
In summary, we have demonstrated that the estimated Mtb specific CD8+ T cell response decreased by 58.4% at 24 weeks, with the majority of the decrease noted (38.7%) at 8 weeks in subjects receiving successful antituberculosis treatment. Our data support the hypothesis that the frequency of Mtb specific CD8+ T cells, potentially as consequence of decreasing intracellular mycobacterial antigens, declines with antituberculosis therapy and may prove to be a surrogate marker of response to therapy. In contrast, the association of the Mtb specific CD4+ response with treatment was marginal, and affected by underlying malnutrition. At present, additional research is needed into the Mtb specific CD8+ T cell response during treatment at earlier time points (prior to 8 weeks), in subjects who fail treatment, and in subjects with HIV/TB coinfection. Such research would help to evaluate the practical application of the frequency of Mtb specific CD8+ T cells as a reliable and useful surrogate marker of response to therapy that may be used alone or in combination with other immune surrogates of antigen load
The authors acknowledge the invaluable contribution made by the study medical officers, health visitors, and laboratory personnel, including Grace Muzanyi, medical officer for patient care; Joseph Nakibali, James Kimera, and Elias Ssaku, home health visitors for DOT supervision, patient support and defaulter tracing. In addition, the authors would like to acknowledge the contributions of Pierre Peters with the immunology laboratory and Sam Ogwang, Kathy Eisenach, and Moses Joloba with the microbiology laboratory. The authors thank Christina Lancioni for her helpful comments on the manuscript. Finally, this study would not be possible without the generous participation of the Ugandan patients and families.